Categories Retail, U.S. Markets News
Johnson & Johnson: Key points on the asbestos report and stock slide
Johnson & Johnson’s (JNJ) stock fell over 8% in intraday trade on Friday after Reuters published a report stating that the company was aware that its baby powder contained the carcinogenic asbestos. The consumer products company has thousands of lawsuits pending over claims that its baby powder has led to cancer.
Here are some key points from the report:
# Reuters went through company memos, internal reports and other confidential documents, along with deposition and trial testimony, which showed that from 1971 to the early 2000s, J&J’s raw talc and finished powders tested positive for small amounts of asbestos occasionally and that the company did not disclose it to regulators or the public.
# The documents also show that efforts to influence the plans of US regulators to limit asbestos in cosmetic talc products and scientific research on the health effects of talc were successful.
# Several reports from J&J’s scientists and external labs identified contaminants in talc and finished powder products as asbestos or described them in terms typically applied to asbestos.
It’s a whopping $4.7 billion penalty for Johnson & Johnson in talcum powder case!
# In 1976, the US FDA was considering limits on asbestos in cosmetic talc products. During this time, despite at least three tests by three different labs from 1972 to 1975 finding asbestos in its talc, including a case of reportedly high levels, J&J told the agency that no asbestos was found in any sample of talc produced between December 1972 and October 1973.
Ernie Knewitz, J&J’s vice president of global media relations, wrote in an emailed response to Reuters’ findings, “Plaintiffs’ attorneys out for personal financial gain are distorting historical documents and intentionally creating confusion in the courtroom and in the media. This is all a calculated attempt to distract from the fact that thousands of independent tests prove our talc does not contain asbestos or cause cancer. Any suggestion that Johnson & Johnson knew or hid information about the safety of talc is false.”
Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on